For research use only. Not for therapeutic Use.
JAK-IN-25 (compound 19) is a potent JAK inhibitor with IC50s of 6 nM, 21 nM, 8 nM, 1051 nM for TYK2, JAK1, JAK2, JAK3, respectively. JAK-IN-25 inhibits human whole blood IL-12 (HEB IL-12) with an IC50 of 28 nM. JAK-IN-25 has the potential for cancer research[1].
| Catalog Number | I041158 |
| CAS Number | 2127110-22-7 |
| Synonyms | methyl 6-[1-[(4-methoxyphenyl)methyl]pyrazol-4-yl]-4-oxo-5H-pyrazolo[1,5-a]pyrazine-2-carboxylate |
| Molecular Formula | C19H17N5O4 |
| Purity | ≥95% |
| InChI | InChI=1S/C19H17N5O4/c1-27-14-5-3-12(4-6-14)9-23-10-13(8-20-23)16-11-24-17(18(25)21-16)7-15(22-24)19(26)28-2/h3-8,10-11H,9H2,1-2H3,(H,21,25) |
| InChIKey | KJSUDTXSTRQSEJ-UHFFFAOYSA-N |
| SMILES | COC1=CC=C(C=C1)CN2C=C(C=N2)C3=CN4C(=CC(=N4)C(=O)OC)C(=O)N3 |
| Reference | [1]. Matthew Frank Brown, et al. Pyrazolo[1,5-a]pyrazin-4-yl derivatives. US20230045252A1. |
